Transcription
Hi, I'm Derek Mueller, PA from Detroit, Michigan, and I'm here live at ACR 2026 in Orlando, Florida. This morning, I had the pleasure of attending a very insightful session about the modern understanding of evaluation and diagnosis of Sjögren's disease. And this was presented this morning by Dr. Gaith Noaiseh from the University of Kansas.
So I'm going to tell you six suggestions that he talked about that could be particularly relevant in the practice of evaluating and diagnosing Sjögren's disease that I took away from this.
Number one, Sjögren's disease is not a linear disease. This is not a condition that begins as sicca and then in a linear fashion progresses to systemic. That's not the case. Patients may present with the systemic manifestation first and then sicca later, or maybe not ever sicca at any point in time, and also patients may present with lymphoma as their sentinel Sjögren's-defining event.
Number two, ACR and EULAR classification criteria should not be used in the diagnosis from a clinical standpoint. They're very informative, but these do not replace your clinical judgment, especially in cases where Sjögren's disease is early and may not necessarily meet the stringent criteria of classification. It's always something I think to be privy to. And also of note, understand that that same classification criteria also allows you to think about alternative diagnoses that could be in the mix and look like Sjögren's, like HIV or sarcoidosis, hepatitis C virus, and what have you.
Number three, there can be a mismatch between the various scoring systems that are utilized in clinical trials for Sjögren's disease — namely the ESSDAI and the ESSPRI. The ESSDAI being more of a global assessment of the various organ domains that are relevant in Sjögren's disease, and also the ESSPRI being more of a patient-reported assessment of symptom severity. So this is a problem in other disease states such as SLE, where there can be disagreement between the measurements we use and clinically how those are relevant, and that can add to a challenge that we see in approving new therapies for Sjögren's.
Number four, lymphoma risk. Dr. Noaiseh discussed various factors that we can think about that may enhance a Sjögren's patient's lymphoma risk over the long term. The most well-established risk factors for lymphoma include persistent salivary gland enlargement, cryoglobulinemia presence, low C4, and rheumatoid factor — although those last two kind of go along with cryoglobulinemia in a way. And also some other factors to think about, maybe less established, would be the presence of purpuric rash, Raynaud's phenomenon, monoclonal gammopathy, and the presence of Sjögren's antibodies.
Number five, the absence of sicca is a legitimate issue and is something that is seen and observed in patients who have Sjögren's disease. The absence of sicca can be particularly prevalent in those with young age of onset of Sjögren's disease as well as those who have predominant neuropathy associated with Sjögren's, and that includes the small fiber neuropathy variant.
And lastly, number six, when we're assessing sicca symptoms in suspected Sjögren's patients, we should be sure to ask questions that relate more to function, that get more to the point of Sjögren's and that may be more specific. It's not enough to ask a patient, do you have dry eyes and do you have dry mouth? Those aren't necessarily very informative questions. Functional questions would include those such as: Mrs. Smith, are you having trouble eating? Do you feel like you're not getting enough saliva to swallow your food? Can you eat a saltine cracker without taking a sip of fluid or liquid? And have you ever been at a point in time in your life where you were not able to produce tears? These functional assessments might mean more in the assessment and diagnosis of patients with Sjögren's. Thank you so much.
So I'm going to tell you six suggestions that he talked about that could be particularly relevant in the practice of evaluating and diagnosing Sjögren's disease that I took away from this.
Number one, Sjögren's disease is not a linear disease. This is not a condition that begins as sicca and then in a linear fashion progresses to systemic. That's not the case. Patients may present with the systemic manifestation first and then sicca later, or maybe not ever sicca at any point in time, and also patients may present with lymphoma as their sentinel Sjögren's-defining event.
Number two, ACR and EULAR classification criteria should not be used in the diagnosis from a clinical standpoint. They're very informative, but these do not replace your clinical judgment, especially in cases where Sjögren's disease is early and may not necessarily meet the stringent criteria of classification. It's always something I think to be privy to. And also of note, understand that that same classification criteria also allows you to think about alternative diagnoses that could be in the mix and look like Sjögren's, like HIV or sarcoidosis, hepatitis C virus, and what have you.
Number three, there can be a mismatch between the various scoring systems that are utilized in clinical trials for Sjögren's disease — namely the ESSDAI and the ESSPRI. The ESSDAI being more of a global assessment of the various organ domains that are relevant in Sjögren's disease, and also the ESSPRI being more of a patient-reported assessment of symptom severity. So this is a problem in other disease states such as SLE, where there can be disagreement between the measurements we use and clinically how those are relevant, and that can add to a challenge that we see in approving new therapies for Sjögren's.
Number four, lymphoma risk. Dr. Noaiseh discussed various factors that we can think about that may enhance a Sjögren's patient's lymphoma risk over the long term. The most well-established risk factors for lymphoma include persistent salivary gland enlargement, cryoglobulinemia presence, low C4, and rheumatoid factor — although those last two kind of go along with cryoglobulinemia in a way. And also some other factors to think about, maybe less established, would be the presence of purpuric rash, Raynaud's phenomenon, monoclonal gammopathy, and the presence of Sjögren's antibodies.
Number five, the absence of sicca is a legitimate issue and is something that is seen and observed in patients who have Sjögren's disease. The absence of sicca can be particularly prevalent in those with young age of onset of Sjögren's disease as well as those who have predominant neuropathy associated with Sjögren's, and that includes the small fiber neuropathy variant.
And lastly, number six, when we're assessing sicca symptoms in suspected Sjögren's patients, we should be sure to ask questions that relate more to function, that get more to the point of Sjögren's and that may be more specific. It's not enough to ask a patient, do you have dry eyes and do you have dry mouth? Those aren't necessarily very informative questions. Functional questions would include those such as: Mrs. Smith, are you having trouble eating? Do you feel like you're not getting enough saliva to swallow your food? Can you eat a saltine cracker without taking a sip of fluid or liquid? And have you ever been at a point in time in your life where you were not able to produce tears? These functional assessments might mean more in the assessment and diagnosis of patients with Sjögren's. Thank you so much.
Recommended videos
-
General Rheumatology
QD Clinic: Sjogren's Beyond the Dryness
-
Education/ACR/EULAR
ILD in Sjögren's and Beyond: ACR vs EULAR Guidelines
-
Rheumatoid Arthritis
QD Clinic: RA, IBD and Frank's sign

If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.